Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Mol Imaging Biol. 2020 Feb;22(1):134–143. doi: 10.1007/s11307-019-01356-z

Fig. 6.

Fig. 6.

Immunohistochemical (IHC) staining of a HepG2 tumor and b McA-RH7777 tumor for GPC3 and hematoxylin and eosin (H&E) staining of c HepG2 tumor and d McA-RH7777 tumor (scale bar: 100 μm). The IHC staining confirmed that the HepG2 tumor is GPC3 positive, and the McA-RH7777 tumor is GPC3 negative.